Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes.

ABSTRACT:

Aim/introduction

Xanthine oxidoreductase (XOR) inhibitor treatment, which reduces reactive oxygen species (ROS) production and increases adenosine triphosphate (ATP) synthesis, has been reported to improve glycemic control. The possible protective effects of XOR inhibitor treatment on insulin secretory capacity were investigated in patients with type 2 diabetes.

Materials and methods

This retrospective cross-sectional study included 428 patients with type 2 diabetes. Insulin secretory capacity was assessed based on fasting serum C-peptide concentration (CPR) and C-peptide index (CPI) in all subjects, while insulin resistance in non-insulin users (n = 312) was determined using the homeostasis model assessment of insulin resistance (HOMA-IR) index.

Results

Median values

SUBMITTER: Kitamura A 

PROVIDER: S-EPMC11442858 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature